Navigation Links
DURECT Corporation Announces Fourth Quarter and Year End 2010 Financial Results
Date:3/2/2011

h this product represents a modest revenue opportunity for DURECT by itself, the SABER technology is the basis for our POSIDUR program currently in a pivotal Phase III clinical trial as well as for multiple on-going feasibility projects seeking to deliver proteins and peptides for periods of up to one month from a single injection.


  • Financial Guidance.  Our net cash consumption is heavily influenced by the timing and structure of new corporate collaborations, as well as the achievement of milestones under existing collaborations.  While we anticipate entering into new collaborations in 2011 and beyond, assuming no new collaborations, no milestone or royalty payments and aggressive funding of our R&D programs, many of which are in clinical development, we anticipate our net cash consumption in 2011 will be approximately $23-27 million.


  • Business Development Activities.  We have multiple programs that may potentially be partnered over the next 12-18 months.  These include TRANSDUR-Sufentanil worldwide rights, POSIDUR for Japan, ORADUR-ADHD, as well as various internal programs which we have not described publicly in detail.Earnings Conference CallA live audio webcast of a conference call to discuss 2010 results will be broadcast over the internet at 4:30 p.m. Eastern Time on March 2 and is available by accessing DURECT's homepage at www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

    About DURECT CorporationDURECT is a specialty pharmaceutical compan
    '/>"/>


  • SOURCE DURECT Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective
    2. DURECT Corporation Announces Third Quarter 2008 Financial Results
    3. DURECT Corporation Invites You to Join its Third Quarter 2010 Earnings Conference Call
    4. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
    5. Pharmos Corporation Reports 2008 Second Quarter Results
    6. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
    7. Genaera Corporation Announces Second Quarter Financial Results
    8. MannKind Corporation Reports Second Quarter Financial Results
    9. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
    10. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
    11. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... uBiome, the ... up to $100,000 of microbiome sampling kits and full 16S laboratory analysis. The goal ... well-being. The winner will also have access to their own dashboard, enabling them to ...
    (Date:7/7/2015)... , ... July 07, 2015 , ... ... together to lower barriers to innovation in life science R&D, has attracted a ... last quarter include another top ten pharmaceutical company joining as a Core member, ...
    (Date:7/6/2015)... July 6, 2015  Emdeon Inc. today ... definitive agreement to acquire Altegra Health, a ... that combine data aggregation and analytics with ... achieve actionable insights and improved management for ... Health,s risk adjustment and quality analytics and ...
    (Date:7/6/2015)... 6, 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ... with Novella Clinical (Novella), to conduct the ... newly diagnosed glioblastoma. Novella is a full-service, global clinical ... to mid-sized oncology companies. The ICT-107 phase 3 trial ... Europe and Canada ...
    Breaking Biology Technology:uBiome to Award Grant of up to $100k for Groundbreaking Microbiome Research 2uBiome to Award Grant of up to $100k for Groundbreaking Microbiome Research 3Pistoia Alliance Continues to Attract New Members 2Emdeon to Acquire Altegra Health 2Emdeon to Acquire Altegra Health 3Emdeon to Acquire Altegra Health 4ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2
    ... Zentaris Inc.,(NASDAQ: AEZS ; TSX: AEZ), a ... today announced that it received a letter,from the ... the 30,consecutive business days prior to October 16, ... had closed below the US$1.00 minimum bid per ...
    ... Media Resulted in Increased Yield and Quality of Insulin-Producing Islet ... ... BOTHELL, Wash., Oct. 24 BioLife Solutions,Inc. (OTC Bulletin Board: ... media products for,cells, tissues, and organs, today announced that MicroIslet Inc. ...
    ... IDenta Corp. (Other,OTC: IDTA.PK) released today the ... United States and Oversees markets., - The ... IDenta Corporation continues, has resulted in increasing market,penetration ... Accutest(R) IDenta sales,have increased significantly in the United ...
    Cached Biology Technology:AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price 2AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price 3BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes 2BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes 3BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes 4International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 2International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 3International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 4
    (Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ... America Biomedical Sensors Market - Growth, Trends & Forecasts ... Latin America Biomedical Sensors market is estimated at $0.65 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
    (Date:6/25/2015)... LAKE CITY , June 25, 2015  Imagine ... first steps toward a healthier, happier life. That,s exactly ... is designed to do. The cutting-edge, portable health program ... offers real-life solutions to help improve your lifestyle and ... Association awards dinner and gala Wednesday night, USANA,s THA ...
    (Date:6/24/2015)... YORK , June 24, 2015 This ... market, over the next six years. It contains an ... the industry, along with their impact from the short, ... It also discusses the industry, market, and technology trends ... that the need of concerned authorities to efficiently manage ...
    Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
    ... as a biofuels source has a much longer growing ... secret of its success. Their findings offer a promising ... significantly boost per-acre yields. The new study, from ... Plant Physiology Preview . Miscanthus x giganteus ...
    ... A team of researchers headed by biologists at Washington University ... bacterium that manages two disparate operations photosynthesis and nitrogen ... daily. Himadri B. Pakrasi, Ph.D., George William and ... to sequence the genome of Cyanothece sp. ATCC ...
    ... , Researchers at the U.S. National Institutes of Health ... simple antiviral drug developed decades ago suppresses HIV in patients ... in the Sept. 11 issue of the journal Cell ... led by Dr. Leonid Margolis made the initial discovery, while ...
    Cached Biology News:Giant grass offers clues to growing corn in cooler climes, researchers report 2Cyanobacterium sequenced features rare linear chromosome 2Cyanobacterium sequenced features rare linear chromosome 3Herpes drug inhibits HIV in patients infected with both viruses 2
    One-step, microplate or cuvet, colorimetric, linear detection range 0.6 mM to 100 mM. Procedure: 2 min....
    [5,6,8,9,12,14,15(n)-3H]Prostaglandin D2, 925 kBq, 25 uCi. Methanol:water:acetonitrile (3:2:1) solution.> 3.0 TBq/mmol, > 80 Ci/mmol.3.7 MBq/ml, 100 uCi/ml. Category: Radiochemicals &Radiation Safety...
    EnzChek cellulase substrate *blue fluorescent, 339/452...
    Request Info...
    Biology Products: